Cargando…
Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society of Nephrology. Published by Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276570/ https://www.ncbi.nlm.nih.gov/pubmed/34270945 http://dx.doi.org/10.1016/j.kint.2021.07.004 |
| _version_ | 1783721928683421696 |
|---|---|
| author | Kaiser, Robert A. Haller, Maria C. Apfalter, Petra Kerschner, Heidrun Cejka, Daniel |
| author_facet | Kaiser, Robert A. Haller, Maria C. Apfalter, Petra Kerschner, Heidrun Cejka, Daniel |
| author_sort | Kaiser, Robert A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8276570 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | International Society of Nephrology. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82765702021-07-14 Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients Kaiser, Robert A. Haller, Maria C. Apfalter, Petra Kerschner, Heidrun Cejka, Daniel Kidney Int Letter to the Editor International Society of Nephrology. Published by Elsevier Inc. 2021-09 2021-07-13 /pmc/articles/PMC8276570/ /pubmed/34270945 http://dx.doi.org/10.1016/j.kint.2021.07.004 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Kaiser, Robert A. Haller, Maria C. Apfalter, Petra Kerschner, Heidrun Cejka, Daniel Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients |
| title | Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients |
| title_full | Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients |
| title_fullStr | Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients |
| title_full_unstemmed | Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients |
| title_short | Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients |
| title_sort | comparison of bnt162b2 (pfizer–biontech) and mrna-1273 (moderna) sars-cov-2 mrna vaccine immunogenicity in dialysis patients |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276570/ https://www.ncbi.nlm.nih.gov/pubmed/34270945 http://dx.doi.org/10.1016/j.kint.2021.07.004 |
| work_keys_str_mv | AT kaiserroberta comparisonofbnt162b2pfizerbiontechandmrna1273modernasarscov2mrnavaccineimmunogenicityindialysispatients AT hallermariac comparisonofbnt162b2pfizerbiontechandmrna1273modernasarscov2mrnavaccineimmunogenicityindialysispatients AT apfalterpetra comparisonofbnt162b2pfizerbiontechandmrna1273modernasarscov2mrnavaccineimmunogenicityindialysispatients AT kerschnerheidrun comparisonofbnt162b2pfizerbiontechandmrna1273modernasarscov2mrnavaccineimmunogenicityindialysispatients AT cejkadaniel comparisonofbnt162b2pfizerbiontechandmrna1273modernasarscov2mrnavaccineimmunogenicityindialysispatients |